Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease

Pierre Arnautou; Martine Auclair; Soraya Fellahi; C. Bouché; Claire Fieschi; E. Barrak; Viviane Queyrel‐Moranne; Lucy Chaillous; Nicolas Blin; Marion Malphettes; Jehane Fadlallah; Rémi Bertinchamp; Laurence Gérard; Djaouïda Bengoufa; Lionel Galicier; Éric Oksenhendler; Corinne Vigouroux; David Boutboul

doi:10.1182/bloodadvances.2020002801

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Key Points Autoimmune hypoglycemia belongs to the clinical spectrum of HHV8+ MCD and rituximab is an effective treatment of this condition. This rare complication is related to autoantibodies directed toward the insulin receptor and activating the insulin signaling pathway.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Arnautou et al. (2021) studied this question.

synapsesocial.com/papers/6a80bb30416558f5ced47be9 https://doi.org/10.1182/bloodadvances.2020002801

View Full Paper

Ask AI

Bookmark

Share

Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease

Ask about this paper

Abstract

Discussion

Cite This Study

Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading